Quest Diagnostics (NYSE: DGX) reported second-quarter financial results before the regular market hours on Thursday. The Q2 earnings were a cent higher than the average Wall Street prediction, while the revenues were in line.
DGX shares fell 1.8% immediately following the announcement. The stock has gained 23% since the beginning of the year.
CEO Steve Rusckowski said, “Looking forward to the rest of the year, we will continue to expand COVID-19 testing capacity while also continuing to serve our customers as they continue to recover from the pandemic.”
Prior performance
[irp posts=”66899″]
Most Popular
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
BLK Q4 Preview: BlackRock appears poised for another earnings beat
BlackRock, Inc. (NYSE: BLK), the largest asset management company, is set to publish its fourth-quarter 2025 results next week. The update is expected to shed light on how the firm’s
A look at Best Buy’s (BBY) progress on its growth strategy
Shares of Best Buy Co., Inc. (NYSE: BBY) fell over 3% on Wednesday. The stock has dropped 17% over the past 12 months. The consumer electronics retailer delivered sales and
